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A case of lymphoma of T-cell derivation with aberrant expression of three B-cell lineage markers (CD19, CD20, and CD79a), which
was diagnosed on a left axillary excision, is described. Immunohistochemical studies and flow cytometry analysis demonstrated
neoplastic cells expressing CD3, CD19, CD20, and CD79a with absence of CD4, CD8, CD10, CD30, CD34, CD56, CD68, TDT,
MPO, PAX-5, and surface immunoglobulin. Gene rearrangement studies performed on paraffin blocks demonstrated monoclonal
T-cell receptor gamma chain rearrangement with no evidence of clonal heavy chain rearrangement. The neoplastic cells were
negative for Epstein-Barr virus (EBV) or Human Herpes Virus 8 (HHV-8). At the time of diagnosis, the PET scan demonstrated
hypermetabolic neoplastic cells involving the left axilla, bilateral internal jugular areas, mediastinum, right hilum, bilateral lungs,
and spleen. However, bone marrow biopsy performed for hemolytic anemia revealed normocellular bone marrow with trilineage
maturation. The patient had no evidence of immunodeficiency or infection with EBV or HHV-8.This is the first reported case of a
mature T-cell lymphoma with aberrant expression of three B-cell lineage markers. The current report also highlights the need for
molecular gene rearrangement studies to determine the precise lineage of ambiguous neoplastic clones.
1. Introduction
In vast majority of cases, T-cell lymphomas do not express
B-cell markers. However, aberrant expression of one or
two B-cell antigens has been documented. However, there
are no cases reported in the literature of peripheral T-
cell lymphomas expressing three B-cell immunophenotypic
markers.Here, we present a case of a gamma clonal peripheral
T-cell lymphoma expressing CD19, CD20, and CD79a in
an individual with no evidence of immunodeficiency or
infection with EBV or HHV-8.
CD19 is a transmembrane protein that is expressed on
B cells and follicular dendritic cells. CD19 along with CD21
plays an important role in B-cell activation. Aberrant expres-
sion of CD19 has been reported in acute myeloid leukemia
[1, 2]. However, only one case report has described aberrant
expression of only CD19 in mature T-cell lymphoma [3].
CD20 is a B-cell lineage-specific marker expressed on
the surface of all B cells, except the early pro-B cells and
terminal plasma cells.This 37 kDa nonglycosylated phospho-
protein may act as calcium channel in the cell membrane
[4]. Although the exact role of CD20 and its ligand is
still unclear, CD20 is believed to boost T-cell-independent
antibody response [5]. CD20 expression is diagnostic of B-cell
lymphomas, hairy cell leukemia, melanoma, thymoma, and
Hodgkin’s disease. Monoclonal antibodies such as rituximab
and tositumomab target the expression of CD20 on B-cell
leukemia and lymphoma [6, 7]. However, few case reports
demonstrating expression of CD20 in peripheral T-cell lym-
phomas have been reported [8–13].
CD79a (mb-1) protein is associated with IgM. Due to its
association with the B-cell antigen receptor, it is expressed
exclusively on the B cells and is absent in other healthy
immune cells. However, its aberrant expression has been
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Figure 1: (a) Atypical lymphoid infiltrates associated with marked fibrosis (20x magnification) and (b) atypical cells with irregular nuclear
membrane, open chromatin, and distinct nucleoli (200x magnification).
(a) (b)
(c)
Figure 2: (a) Neoplastic cells demonstrating strong CD3 positivity (200x magnification), (b) neoplastic T cells with aberrant CD20 positivity
(100x magnification), and (c) neoplastic T cells with aberrant CD79a positivity (100x magnification).
reported in both B- and T-cell lymphoblastic leukemia [14–
17]. However, similar to the current case report, only one
case report described CD79a expression in a mature T-
cell lymphoma [18]. Interestingly, Yao et al. also reported
an aberrant expression of CD20 along with CD79a in the
gamma clonal T-cell lymphoma. To our knowledge, this is
the first case report of a peripheral mature T cell lymphoma
expressing CD19, CD20, and CD79a B cell markers.
2. Case Presentation
The patient was a 75-year-old Caucasian male who under-
went a left axillary dissection for enlarging lymph nodes
present for more than one year. He denied symptoms of
fatigue, dyspnea, fever, or night sweats. The PET scan
performed at the same time demonstrated hypermetabolic
foci involving the left axilla, bilateral internal jugular areas,
mediastinum, right hilum, bilateral lungs, and spleen. Inter-
estingly, a year ago, he had an episode of hemolytic anemia
for which he completed a one-year course of oral prednisone.
Further evaluation of clinical history revealed that he was
diagnosed two years back with reactive cervical lymph node
at an outside hospital. Moreover, five years before the current
diagnosis of T-cell lymphoma, the patient also had sinus his-
tiocytosis involving level 7 neck lymph node. His past history
was significant for vocal cord resection for tumor more than
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Figure 3: Flow cytometry demonstrating aberrant T cells expressing CD3 and CD19, weak CD7, and absent CD4, CD8, and CD10 expression.
40 years ago. His social history was significant for exposure
to asbestos as a construction worker. His father and two
uncles died of prostate cancer. There was no family history
of hematological malignancies or blood cell dyscrasias.
The histological sections demonstrated an effaced nodal
architecture with proliferation of large atypical lymphoid
infiltrates associated with marked fibrosis (Figure 1(a)). The
atypical cells showed irregular nuclear membrane, open
chromatin, and distinct nucleoli (Figure 1(b)).The neoplastic
cells stained strongly and diffusely positively for CD3 with
partial loss of CD5 and CD7 (Figure 2(a)). A subpopulation
of the neoplastic cells was positive for CD20 and CD79a
(Figures 2(b) and 2(c)). The neoplastic cells were negative
by immunohistochemistry for CD4, CD8, CD10, CD30,
CD34, CD56, CD68, TDT, MPO, PAX-5, EBV, and HHV8.
Further review of flow cytometry histograms demonstrated
an aberrant T-cell population, which expressed CD19 along
with CD3 and CD20 (Figure 3). The gene rearrangement
studies for immunoglobulin and T-cell receptors were per-
formed by ARUP laboratories Inc., Salt lake City, Utah, by
performing polymerase chain reaction on the DNA extracted
from paraffin embedded blocks.The T-cell clonality was con-
firmed by gene rearrangement studies showing gamma clonal
T-cell receptor rearrangement with absence of immunoglob-
ulin chain gene rearrangement.
3. Discussion
The current case report demonstrates the need to utilize
genetic rearrangement studies to determine the precise lin-
eage for neoplastic clones expressing biphenotypic markers
by flow cytometry and immunohistochemistry. It is possible
to misdiagnose the current case as a large B-cell lymphoma
expressing CD19, CD20, and CD79a. Interestingly, five years
prior to the diagnosis of peripheral T-cell lymphoma, the
patient had a previous diagnosis of sinus histiocytosis on a
level 7 lymph node excision. In addition, three years later, he
was diagnosed with a reactive cervical lymph node at an out-
side hospital. Unfortunately, at the time of diagnosis, the PET
scan demonstrated hypermetabolic neoplastic cells involving
the left axilla, bilateral internal jugular areas, mediastinum,
right hilum, bilateral lungs, and spleen. However, bone
marrow biopsy performed for hemolytic anemia revealed
normocellular bone marrow with trilineage maturation.
The current case demonstrates an unusual occurrence of
genetic dysregulation involving three B-cell specific lineage
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markers leading to lineage infidelity. This genetic dysregula-
tion may involve transcription factors regulating the expres-
sion of B-cell markers. Recently, it has been demonstrated
that PAX-5 induces transcriptional activation of CD19 and
CD79a in B cells [19]. However, in our case, the T-cell neo-
plastic clone did not express PAX-5, by immunohistochem-
istry. In addition, lineage infidelity may be demonstrated in
the presence of immunodeficiency and infection with EBV or
HHV-8 [20–22]. In the current case, the patient did not show
any evidence of immunodeficiency. Immunohistochemistry
of the neoplastic cells was negative for EBV and HHV-8.
The findings in our case suggest a T-cell lymphoma
belonging to the 𝛾𝛿 T-cell lineage. Interestingly, the tumor
was positive for CD3 but was negative for CD56 that is
expressed on 𝛾𝛿 T-cell lymphomas [23, 24]. Based on the
involvement of tissues by neoplastic cells by PET scan, the
neoplastic clone reported in our study showed an aggressive
clinical behavior. However, the current patient showed an
excellent response to six cycles of CHOP chemotherapy
regimen along with Rituxan. Unfortunately, a follow-up CT
scan three months later showed progression of lung nod-
ules. He subsequently underwent salvage chemotherapy with
three cycles of ICE chemotherapy regimen. A follow-up CT
scan showed complete response after three cycles of ICE
chemotherapy with no evidence of pulmonary nodules. In
addition, his bone marrow biopsy showed no evidence of
involvement by neoplastic cells.
Thus, the current study demonstrates that the use of
more than one B-cell marker by flow cytometry or immuno-
histochemistry may not be able to precisely identify the
lineage of neoplastic clones. In these cases of lineage infidelity,
genetic rearrangement studies are invaluable for providing a
conclusive answer.Moreover, the aberrant expression of three
B-cell markers in a peripheral T-cell lymphoma suggests a
high degree of transcriptional dysregulation of genes, which
may be closely linked to initiation and/or proliferation of the
neoplastic clone.
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